Allakos (Allakos) Debt-to-Asset

: 0.17 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Allakos's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.25 Mil. Allakos's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $38.22 Mil. Allakos's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $243.61 Mil. Allakos's debt to asset for the quarter that ended in Dec. 2023 was 0.17.

Allakos Debt-to-Asset Historical Data

The historical data trend for Allakos's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.02

0.06

0.10

0.13

0.17

Allakos Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset																0.13	0.12	0.13	0.15	0.17

Competitive Comparison

For the Biotechnology subindustry, Allakos's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allakos Debt-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Allakos's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Allakos's Debt-to-Asset falls into.

Allakos Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Allakos's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.25	+	38.215)	/	243.61
	=	0.17

Allakos's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.25	+	38.215)	/	243.61
	=	0.17

Allakos (NAS:ALLK) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Allakos Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Allakos's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos (Allakos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

37Z:Germany

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Executives

Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Amy L Ladd	director	INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson	officer: Chief Medical Officer	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald	officer: General Counsel and Secretary	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James	director	C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi	officer: COO, CFO and Secretary	ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander	director, officer: President and CEO	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Harlan Baird Radford	officer: Chief Financial Officer	C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Rasmussen Henrik S Md	officer: Chief Medical Officer	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn	director, 10 percent owner	5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson	10 percent owner	701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067